TABLE 2.
Summary of in vitro studies for atazanavir and atazanavir/ritonavir
| Drug | EC50 (µM) | CC50 (µM) | Cell line | Postinfection treatment time (h) | MOI | Virus quantification method | fu*PK/EC50 | Reference |
|---|---|---|---|---|---|---|---|---|
| Atazanavir | >50 | >50 | Vero | 72 | 0.05 | Viral cytopathic effect | <0.02 | 4 |
| Atazanavir | 0.22 | 312 | Human epithelial pulmonary (A549) | 48 | 0.01 | qRT‐PCR | 4.69 | 5 |
| Atazanavir | 2.0 | 312 | Vero | 48 | 0.01 | qRT‐PCR | 0.52 | 5 |
| Atazanavir | 9.36 | >81 | VeroE6/TMPRSS2 | 24 | 0.01 | qRT‐PCR | 0.11 | 6 |
| Atazanavir/ritonavir | 0.5 | 280 | Vero | 48 | 0.01 | qRT‐PCR | 2.07 | 5 |
| Atazanavir/ritonavir | 0.6 | 280 | Human epithelial pulmonary (A549) | 48 | 0.01 | qRT‐PCR | 1.72 | 5 |
Abbreviations: CC50, the drug concentration that reduces the total cell number by 50%; EC50, the drug concentration that inhibits 50% of the virus; MOI, multiplicity of infection; PK, pharmacokinetic; qRT‐PCR, quantitative real‐time reverse transcription–polymerase chain reaction; TMPRSS2, transmembrane serine protease 2.